Skip to main content

Cell and Gene Therapy Market is Rapidly Driven by Innovations Current Trends, New Development and Future Opportunities

 The cell and gene therapy market is the upcoming wave of therapeutic innovation in the healthcare and life sciences industry. However, the technology for manufacturing these therapies are still in t nascent stage. Furthermore, in 2020 significant number of financing was received by the company for cell and gene therapies in spite of economic challenges due to COVID-19 spread. The year was record breaking and the therapeutic developers of the cell and gene therapies raised more in the first half of the year than in the complete year 2019. 

Cell and gene therapy are overlapping fields of biomedical research having similar therapeutic goals, which target DNA or RNA inside or outside the body. Both therapies aim at modifying genetic material for treatment of a disease. Gene therapy uses genetic material, or DNA, to manipulate a patient’s cells for the treatment of an inherited or acquired disease. Cell therapy is the introduction of new cells into a patient’s body to grow, replace or repair damaged tissue to treat a disease. The cell and gene therapies are categorized into several therapeutic class, such as rare diseases, oncology, hematology, cardiovascular, ophthalmology, neurology, and others.

The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is expected to grow at an impressive double-digit rate of 33.82% and reach a value of $25,002.1 million in 2027.

The existing cell and gene therapy market is favored by multiple factors, which include increasing incidences of cancer and other chronic diseases, rising number of clinical trials, increasing funding and investments in the cell and gene therapy market, and favorable regulatory environment and FDA Approvals for cell and gene therapy products.

View the Report on BIS Research - Global Cell and Gene Therapy Market

Competitive Landscape

The global cell and gene therapy market witnessed 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions. 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions.

Major players within the cell and gene therapy market are Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.

Market Segmentation

• By Product Type: Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-Cel, Zyntelego, Others

• By Therapeutic Class: Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology and Other Therapeutic Classes

• By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Regional Segmentation

• North America – Country Specific Stratification

• Europe – Country Specific Stratification

• Asia-Pacific – Country Specific Stratification

• Latin America – Country Specific Stratification

• Rest-of-the-World

 Cell and Gene Therapy Market Dynamics

 

 

Key Cell and Gene Therapy Companies Profiled

Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.

 

Key Questions Answered in this Report:

•    What are the different types of approved cell and gene therapies available in the respective market?
•    What are the key development strategies implemented by the key players to stand out in this market?
•    What are the various manufacturing considerations within the cell and gene therapy market?
•    How have the strategic collaborations among the key players providing a push to product development within the global cell and gene therapy market? 
•    What are the regulations pertaining to the global cell and gene therapy market in different regions?
•    What are the initiatives implemented by different government bodies regulating the development and commercialization of cell and gene therapy products and associated platforms?
•    How has COVID-19 impacted the cell and gene therapy market?
•    How will the urgency of the pandemic influence the global cell and gene therapy market?
•    What are the leading companies dominating the global cell and gene therapy market?
•    What is the reimbursement scenario of the products offered in the global cell and gene therapy market?
•    Based on the product type, which therapy in the global cell and gene therapy market is anticipated to witness a massive rise in demand in the forecast period?
•    How is each segment of the global cell and gene therapy market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2027?

Get Free Sample Report - https://bisresearch.com/requestsample?id=1062type=download

Within the research report, the market is segmented on the basis of product type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), therapeutic class type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), and region (North America, Europe, Asia Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among other analyses, to detail the scope and provide a 360-coverage of the domain.

BIS Research Related Market Studies:

Global CRISPR Gene Editing Market - Analysis and Forecast, 2020-2030

Labels

Labels:

Comments

Post a Comment

Popular posts from this blog

Pharmacogenomics Services Market Dynamics, Competitive Landscape & Forecast to 2031

  BIS healthcare experts have found the pharmacogenomics services industry to be one of the most rapidly evolving and dynamic markets. The global  pharmacogenomics services market  is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. The market is driven by certain factors, including increasing prevalence of infectious diseases and various types of cancer, increasing adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Currently, the pharmacogenomics services industry is witnessing an upsurge due to the increasing prevalence of infectious diseases and various types of cancer, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogen...
Post a Comment
Read more

Global Liquid Biopsy Market is Projected to Reach $12,933 Million by 2030

 According to a new market intelligence report by BIS Research titled ‘Global Liquid Biopsy Market – Analysis and Forecast, 2020-2030’, The liquid biopsy market is projected to reach $12,933 million by 2030 from $2588.6 million in 2019, at a CAGR of 15.87% during the forecast period 2020-2030 BIS Research Report: https://bisresearch.com/industry-report/global-liquid-biopsy-market.html   This growth has been primarily attributed to the rising number of cancer cases coupled up with the growing awareness pertaining to non-invasive detection approaches, the increasing adoption of inorganic growth strategies by key players in the market, and the increasing research funding from the leading organizations such as the U.S. National Institute of Health, globally. The market is expected to grow at a significant growth rate due to opportunities such as the introduction of informatics and technological innovations for a large customer base and increasing adoption of cancer and other disea...
Post a Comment
Read more

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more